Payment overview · 2025
General Payments
$83.55
5 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher R Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATHENS, TX · NPI 1942237078
Verified facts
What the public records show
CMS Open Payments records show Christopher R Johnson, M.D. received $83.55 in general payments during 2025 across 5 reported records.
Boston Scientific Corporation accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30.89 | 37.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.30 | 23.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.42 | 22.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.94 | 17.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.55 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 466 | 133 |
| Losartan Potassium | Losartan Potassium | 444 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 100 |
| Lisinopril | Lisinopril | 395 | 96 |
| Carvedilol | Carvedilol | 380 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 91 |
| Gabapentin | Gabapentin | 291 | 68 |
| Meloxicam | Meloxicam | 267 | 68 |
| Tramadol Hcl | Tramadol Hcl | 223 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 56 |
| Metformin Hcl | Metformin Hcl | 188 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 44 |
| Furosemide | Furosemide | 160 | 48 |
| Alprazolam | Alprazolam | 159 | 32 |
| Simvastatin | Simvastatin | 152 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 45 |
| Potassium Chloride | Potassium Chloride | 130 | 37 |
| Sertraline Hcl | Sertraline Hcl | 130 | 33 |
| Donepezil Hcl | Donepezil Hcl | 118 | 29 |
| Spironolactone | Spironolactone | 110 | 26 |
| Jardiance | Empagliflozin | 109 | 15 |
| Glimepiride | Glimepiride | 108 | 27 |
| Famotidine | Famotidine | 105 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 32 |
| Clonazepam | Clonazepam | 96 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 95 | 26 |
| Cefdinir | Cefdinir | 92 | 63 |
| Celecoxib | Celecoxib | 92 | 23 |
| Omeprazole | Omeprazole | 92 | 26 |
| Pregabalin | Pregabalin | 85 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 14 |
| Prednisone | Prednisone | 77 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 20 |
| Colestipol Hcl | Colestipol Hcl | 70 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 12 |
| Eliquis | Apixaban | 65 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 63 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 63 | 14 |
| Synthroid | Levothyroxine Sodium | 62 | 16 |
| Allopurinol | Allopurinol | 60 | 14 |
| Azithromycin | Azithromycin | 59 | 53 |
| Januvia | Sitagliptin Phosphate | 56 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 13 |
| Montelukast Sodium | Montelukast Sodium | 55 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 13 |
| Linzess | Linaclotide | 54 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 11 |
| Mirtazapine | Mirtazapine | 52 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 13 |
| Ozempic | Semaglutide | 50 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 14 |
| Felodipine Er | Felodipine | 45 | 14 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 19 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 15 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 12 |
| Finasteride | Finasteride | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 25 |
| Ondansetron Odt | Ondansetron | 31 | 12 |
| Ramipril | Ramipril | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 13 |
| Glipizide | Glipizide | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.55 · 5 records | Boston Scientific Corporation | Dexcom G6 Transmitter, ECC Solutions, General - Therapies, WaveWriter Alpha Prime 16, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error